Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

McGill University

$27,000.00

Molecular signatures of synergy

FY 2010-11

Summary
Drugs that act against individual molecular targets are often insufficient to combat fungal infections, multigenic diseases such as cancer, and multiple cell or tissue type diseases including immune and inflammatory disorders. Multicomponent therapies that impact several targets simultaneously are less prone to the development of drug resistance, and increase therapeutic efficacy. One of the major benefits of multicomponent therapies is the potential for synergistic effects: that is, the overall therapeutic benefit of the drug combination is greater than the sum of the effects of the individual agents. In particular, synergies between the constituent compounds can provide broader pharmacological windows and reduced toxicity. There are many challenges associated with the identification of molecular synergy and it appears that such synergies are rare. In fact, even for the well-studied yeast, only ~20 synergies are known. High-throughput screens can examine on the order of several thousand of compound pairs, but this represents a very small fraction of the exponential number of chemical combinations available. If we consider that there are >10 million compounds in screening libraries, it is unlikely that experimental techniques will be sufficient to completely survey the vast space of only pairwise synergies (~1013 pairs) in a cost effective and timely fashion. There is a clear need for an approach that winnows this space to a manageably large set of combinations that is enriched for synergistic combinations. We propose to construct a combined genomics and bioinformatics approach to identify and characterize molecular synergies. Using high-throughput gene expression profiles generated from yeast or human cell lines subjected to a single chemical perturbation, our de novo bioinformatics tool will predict pairs of chemical compounds which are highly likely to exhibit a pair-wise synergistic affect. Moreover, analysis of the downstream transcriptional changes caused by the pair of drugs, either in combination or individually, will provide fundamental insight into the molecular nature of synergy.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
238978-2010
Name nom
Hallett, Michael
Department département
Computer Science, School of
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
27000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
2957
Research subject group en
Applied mathematics
Research subject group fr
Mathématiques appliquées
Research subject en
Mathematical biology andphysiology
Research subject fr
Mathématiques de la biologie et de la physiologie
Partie
1
Nb partie
1
Application title
Molecular signatures of synergy
Keyword
NSERC
Application summary
Drugs that act against individual molecular targets are often insufficient to combat fungal infections, multigenic diseases such as cancer, and multiple cell or tissue type diseases including immune and inflammatory disorders. Multicomponent therapies that impact several targets simultaneously are less prone to the development of drug resistance, and increase therapeutic efficacy. One of the major benefits of multicomponent therapies is the potential for synergistic effects: that is, the overall therapeutic benefit of the drug combination is greater than the sum of the effects of the individual agents. In particular, synergies between the constituent compounds can provide broader pharmacological windows and reduced toxicity. There are many challenges associated with the identification of molecular synergy and it appears that such synergies are rare. In fact, even for the well-studied yeast, only ~20 synergies are known. High-throughput screens can examine on the order of several thousand of compound pairs, but this represents a very small fraction of the exponential number of chemical combinations available. If we consider that there are >10 million compounds in screening libraries, it is unlikely that experimental techniques will be sufficient to completely survey the vast space of only pairwise synergies (~1013 pairs) in a cost effective and timely fashion. There is a clear need for an approach that winnows this space to a manageably large set of combinations that is enriched for synergistic combinations. We propose to construct a combined genomics and bioinformatics approach to identify and characterize molecular synergies. Using high-throughput gene expression profiles generated from yeast or human cell lines subjected to a single chemical perturbation, our de novo bioinformatics tool will predict pairs of chemical compounds which are highly likely to exhibit a pair-wise synergistic affect. Moreover, analysis of the downstream transcriptional changes caused by the pair of drugs, either in combination or individually, will provide fundamental insight into the molecular nature of synergy.